Vimta Labs Ltd.
Fundamentals
- Market cap
- ₹2,671 cr
- P/E
- 34.46×
- ROE
- 16.97%
- Debt / equity
- 0.01
- Div yield
- 0.34%
- 52-week range
- 376.05 — 902.65
Analysis — the numbers vs the call
- Vimta Labs' biologics milestone collides with a disclosure U-turn
The first commercial order is real progress, but management's refusal to quantify capacity undermines the capital-spending story.
Company snapshot
Vimta Labs Ltd.
Diagnostic Chains
₹2,683 cr
P/E 33.69×
Latest quarter · Dec 2024
Sales₹90 cr
Net profit₹21 cr
Op. margin+36.8%
EPS₹4.84
Strength & growth
Debt / equity0.06×
Current ratio2.91×
Sales CAGR+12.1%
EPS CAGR+24.8%
The timeline — 3 notes on Vimta Labs Ltd.
July 2026
- 20 Jul 26 · 5:06 PM IST Brief Brief · Concalls · Small cap
Vimta Labs lands first biologics order, budgets ₹80 cr capex for FY27
Q1 results were already disclosed; the concall adds the domestic biologics win and a ₹80 cr capex plan, including ₹10 cr for the new unit.
- 20 Jul 26 · 3:29 PM IST Brief Brief · Earnings · Small cap
Vimta Labs Q1 revenue up 13.7%, EBITDA margin at 36.4%
Steady pharma testing demand and domestic gains offset food testing weakness. Entry into biologics CRD adds a long-term growth lever.
- 20 Jul 26 · 1:44 PM IST Brief Brief · Earnings · Small cap
Vimta Labs Q1: Revenue up 12%, PAT up 11% — steady but not a catalyst
In-line quarter with single-digit profit growth; no guidance change. ESOP grant routine.